MacroGenics Inc (MGNX) SVP Sells $53,100.00 in Stock
MacroGenics Inc (NASDAQ:MGNX) SVP Thomas Spitznagel sold 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $30.00, for a total transaction of $53,100.00. Following the sale, the senior vice president now owns 1,770 shares in the company, valued at approximately $53,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of MGNX opened at $22.44 on Monday. MacroGenics Inc has a 52 week low of $9.87 and a 52 week high of $32.74.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC purchased a new position in MacroGenics during the fourth quarter valued at approximately $65,000. Meeder Asset Management Inc. grew its position in MacroGenics by 4,851.9% during the fourth quarter. Meeder Asset Management Inc. now owns 12,033 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 11,790 shares in the last quarter. Sun Life Financial INC grew its position in MacroGenics by 58.0% during the fourth quarter. Sun Life Financial INC now owns 12,947 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 4,751 shares in the last quarter. Verition Fund Management LLC purchased a new position in MacroGenics during the third quarter valued at approximately $202,000. Finally, Keybank National Association OH purchased a new position in MacroGenics during the third quarter valued at approximately $203,000. 87.47% of the stock is currently owned by hedge funds and other institutional investors.
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
See Also: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.